SCHEMBL16635822

SCHEMBL16635822

COC(=O)C1CC(F)CCC1c1nc(C)sc1-c1ccc(N2CCOCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.39
ADORA1 P30542 2/20 0.39
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
CDK2 P24941 2/20 0.36
AURKA O14965 1/20 0.36
CDK4 P11802 1/20 0.36
AURKB Q96GD4 1/20 0.36
LGMN Q99538 1/20 0.36
CYP3A4 P08684 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CFTR P13569 3/20 0.36
MTOR P42345 2/20 0.35
NPC1 O15118 2/20 0.35
MAPT P10636 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16635820 1.00 ADORA2A (0.39) ADORA2AADORA1JAK2JAK1CDK2
SCHEMBL16635965 0.90 CFTR (0.39) ADORA2AADORA1JAK2JAK1CDK2
SCHEMBL16635676 0.90 CFTR (0.39) ADORA2AADORA1JAK2JAK1CDK2
SCHEMBL18531338 0.89 PARP1 (0.38) ADORA2AADORA1JAK2JAK1CDK2
SCHEMBL24018942 0.85 CTSK (0.46) JAK2JAK1CDK2CDK9CTSK
SCHEMBL16636423 0.83 CTSK (0.37) ADORA2AADORA1JAK2JAK1CDK2
SCHEMBL16635777 0.83 CTSK (0.53) CTSK
SCHEMBL24018857 0.83 CTSK (0.53) CTSK
SCHEMBL18531332 0.78 CTSK (0.44) JAK2KDM4EALDH1A1CTSK
SCHEMBL18531357 0.78 CTSK (0.36) JAK2CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054947-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2021-11-17 EP disclosed
US-9573913-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2017-02-21 US disclosed
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-25 US disclosed
EP-3054947-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054038-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244417-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ ADORA2A 4591/4885ADORA1 4277/4885JAK2 3823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.